Cargando…

Quality of Life in Women with Heavy Menstrual Bleeding Associated with Uterine Fibroids: Baseline Disease Burden from Elaris UF-1 and UF-2

STUDY OBJECTIVE: Report baseline Uterine Fibroid Symptoms Quality of Life Questionnaire (UFS-QoL) data from Elaris UF-1 and UF-2 to characterize disease burden from heavy menstrual bleeding (HMB) associated with uterine fibroids (UF). DESIGN: Elaris UF-1 (NCT02654054) and UF-2 (NCT02691494) were ide...

Descripción completa

Detalles Bibliográficos
Autores principales: Gillispie, V., Al-Hendy, A., Kim, J.H., Wang, A., Kumar, M., Eichner, S., Xue, Z., Schlaff, W.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Published by Elsevier Inc. 2020
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7572045/
http://dx.doi.org/10.1016/j.jmig.2020.08.177
_version_ 1783597267849052160
author Gillispie, V.
Al-Hendy, A.
Kim, J.H.
Wang, A.
Kumar, M.
Eichner, S.
Xue, Z.
Schlaff, W.
author_facet Gillispie, V.
Al-Hendy, A.
Kim, J.H.
Wang, A.
Kumar, M.
Eichner, S.
Xue, Z.
Schlaff, W.
author_sort Gillispie, V.
collection PubMed
description STUDY OBJECTIVE: Report baseline Uterine Fibroid Symptoms Quality of Life Questionnaire (UFS-QoL) data from Elaris UF-1 and UF-2 to characterize disease burden from heavy menstrual bleeding (HMB) associated with uterine fibroids (UF). DESIGN: Elaris UF-1 (NCT02654054) and UF-2 (NCT02691494) were identical, phase 3, double-blind, randomized, placebo-controlled studies investigating safety and efficacy of elagolix alone or combined with hormonal add-back therapy for HMB associated with UF. SETTING: Outpatient in clinic/office. PATIENTS OR PARTICIPANTS: Premenopausal women (n=790) aged 18–51 years with diagnosed UF and HMB (menstrual blood loss [MBL] >80 mL/cycle for ≥2 menses). INTERVENTIONS: N/A MEASUREMENTS AND MAIN RESULTS: A modified UFS-QoL (4-week recall) was conducted before study drug administration. UFS-QoL is a self-administered, 37-item, disease-specific questionnaire that measures symptom severity and health-related QoL (HRQoL; calculated from 6 subscales and scored 0–100). Lower HRQoL scores indicate worse QoL. At baseline, mean (standard deviation [SD]) age was 42.4 (5.4) years, and MBL was 239.7 (158.7) mL. Baseline total HRQoL score was low, reflecting low QoL (mean [SD], 42.9 [23.2]). Mean (SD) scores were generally low across HRQoL domains (concern, 28.1 [24.6]; activities, 40.9 [27.0]; energy/mood, 47.4 [25.3]; control, 54.2 [28.3]; self-consciousness, 39.9 [30.7]; sexual function, 47.5 [35.4]). In each HRQoL domain, the questions most frequently answered ‘most’ or ‘all’ of the time were how often symptoms made patients: feel concerned about soiling underclothes (80%; concern), decrease the amount of time on exercise or other physical activities (59%; activities), feel tired or worn out (68%; energy/mood), feel less productive (50%; control), feel conscious about the size and appearance of their stomach (57%; self-consciousness), and avoid sexual relations (46%; sexual function). CONCLUSION: There was considerable baseline disease burden. Patients reported the greatest impacts to concern and self-consciousness. Common issues included concerns about soiling underclothes and feeling tired or worn out.
format Online
Article
Text
id pubmed-7572045
institution National Center for Biotechnology Information
language English
publishDate 2020
publisher Published by Elsevier Inc.
record_format MEDLINE/PubMed
spelling pubmed-75720452020-10-20 Quality of Life in Women with Heavy Menstrual Bleeding Associated with Uterine Fibroids: Baseline Disease Burden from Elaris UF-1 and UF-2 Gillispie, V. Al-Hendy, A. Kim, J.H. Wang, A. Kumar, M. Eichner, S. Xue, Z. Schlaff, W. J Minim Invasive Gynecol Article STUDY OBJECTIVE: Report baseline Uterine Fibroid Symptoms Quality of Life Questionnaire (UFS-QoL) data from Elaris UF-1 and UF-2 to characterize disease burden from heavy menstrual bleeding (HMB) associated with uterine fibroids (UF). DESIGN: Elaris UF-1 (NCT02654054) and UF-2 (NCT02691494) were identical, phase 3, double-blind, randomized, placebo-controlled studies investigating safety and efficacy of elagolix alone or combined with hormonal add-back therapy for HMB associated with UF. SETTING: Outpatient in clinic/office. PATIENTS OR PARTICIPANTS: Premenopausal women (n=790) aged 18–51 years with diagnosed UF and HMB (menstrual blood loss [MBL] >80 mL/cycle for ≥2 menses). INTERVENTIONS: N/A MEASUREMENTS AND MAIN RESULTS: A modified UFS-QoL (4-week recall) was conducted before study drug administration. UFS-QoL is a self-administered, 37-item, disease-specific questionnaire that measures symptom severity and health-related QoL (HRQoL; calculated from 6 subscales and scored 0–100). Lower HRQoL scores indicate worse QoL. At baseline, mean (standard deviation [SD]) age was 42.4 (5.4) years, and MBL was 239.7 (158.7) mL. Baseline total HRQoL score was low, reflecting low QoL (mean [SD], 42.9 [23.2]). Mean (SD) scores were generally low across HRQoL domains (concern, 28.1 [24.6]; activities, 40.9 [27.0]; energy/mood, 47.4 [25.3]; control, 54.2 [28.3]; self-consciousness, 39.9 [30.7]; sexual function, 47.5 [35.4]). In each HRQoL domain, the questions most frequently answered ‘most’ or ‘all’ of the time were how often symptoms made patients: feel concerned about soiling underclothes (80%; concern), decrease the amount of time on exercise or other physical activities (59%; activities), feel tired or worn out (68%; energy/mood), feel less productive (50%; control), feel conscious about the size and appearance of their stomach (57%; self-consciousness), and avoid sexual relations (46%; sexual function). CONCLUSION: There was considerable baseline disease burden. Patients reported the greatest impacts to concern and self-consciousness. Common issues included concerns about soiling underclothes and feeling tired or worn out. Published by Elsevier Inc. 2020 2020-10-19 /pmc/articles/PMC7572045/ http://dx.doi.org/10.1016/j.jmig.2020.08.177 Text en Copyright © 2020 Published by Elsevier Inc. Since January 2020 Elsevier has created a COVID-19 resource centre with free information in English and Mandarin on the novel coronavirus COVID-19. The COVID-19 resource centre is hosted on Elsevier Connect, the company's public news and information website. Elsevier hereby grants permission to make all its COVID-19-related research that is available on the COVID-19 resource centre - including this research content - immediately available in PubMed Central and other publicly funded repositories, such as the WHO COVID database with rights for unrestricted research re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for free by Elsevier for as long as the COVID-19 resource centre remains active.
spellingShingle Article
Gillispie, V.
Al-Hendy, A.
Kim, J.H.
Wang, A.
Kumar, M.
Eichner, S.
Xue, Z.
Schlaff, W.
Quality of Life in Women with Heavy Menstrual Bleeding Associated with Uterine Fibroids: Baseline Disease Burden from Elaris UF-1 and UF-2
title Quality of Life in Women with Heavy Menstrual Bleeding Associated with Uterine Fibroids: Baseline Disease Burden from Elaris UF-1 and UF-2
title_full Quality of Life in Women with Heavy Menstrual Bleeding Associated with Uterine Fibroids: Baseline Disease Burden from Elaris UF-1 and UF-2
title_fullStr Quality of Life in Women with Heavy Menstrual Bleeding Associated with Uterine Fibroids: Baseline Disease Burden from Elaris UF-1 and UF-2
title_full_unstemmed Quality of Life in Women with Heavy Menstrual Bleeding Associated with Uterine Fibroids: Baseline Disease Burden from Elaris UF-1 and UF-2
title_short Quality of Life in Women with Heavy Menstrual Bleeding Associated with Uterine Fibroids: Baseline Disease Burden from Elaris UF-1 and UF-2
title_sort quality of life in women with heavy menstrual bleeding associated with uterine fibroids: baseline disease burden from elaris uf-1 and uf-2
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7572045/
http://dx.doi.org/10.1016/j.jmig.2020.08.177
work_keys_str_mv AT gillispiev qualityoflifeinwomenwithheavymenstrualbleedingassociatedwithuterinefibroidsbaselinediseaseburdenfromelarisuf1anduf2
AT alhendya qualityoflifeinwomenwithheavymenstrualbleedingassociatedwithuterinefibroidsbaselinediseaseburdenfromelarisuf1anduf2
AT kimjh qualityoflifeinwomenwithheavymenstrualbleedingassociatedwithuterinefibroidsbaselinediseaseburdenfromelarisuf1anduf2
AT wanga qualityoflifeinwomenwithheavymenstrualbleedingassociatedwithuterinefibroidsbaselinediseaseburdenfromelarisuf1anduf2
AT kumarm qualityoflifeinwomenwithheavymenstrualbleedingassociatedwithuterinefibroidsbaselinediseaseburdenfromelarisuf1anduf2
AT eichners qualityoflifeinwomenwithheavymenstrualbleedingassociatedwithuterinefibroidsbaselinediseaseburdenfromelarisuf1anduf2
AT xuez qualityoflifeinwomenwithheavymenstrualbleedingassociatedwithuterinefibroidsbaselinediseaseburdenfromelarisuf1anduf2
AT schlaffw qualityoflifeinwomenwithheavymenstrualbleedingassociatedwithuterinefibroidsbaselinediseaseburdenfromelarisuf1anduf2